APOTEX CORP. for APOTEX CORP.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 4th Quarter - Report (this page) | Jan 20, 2017 | $380,000 | Replaced |
| 4th Quarter - Amendment | Apr 19, 2018 | $460,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Legislation relating to the provision of brand drug products by brand manufacturers to generic manufacturers for development testing, including: H.R. 2841, The FAST Generics Act of 2015; S. 3056, the CREATES Act; H.R. 34, 21st Century Cures Act; and House Energy & Commerce Committee/Senate Health, Education, Labor and Pensions Committee draft legislative proposal.
Foreign entity interest: Aposherm Inc., Apotex Holdings Inc., Sherfam Inc., and Shermco Inc., the parent companies of Apotex Corp. identified on LD-1, have direct or indirect interests in companies that develop, manufacture, and/or sell generic drugs and therefore are interested in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN GIULI | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.